Review: insights into the bile acid-gut microbiota axis in intestinal failure-associated liver disease-redefining the treatment approach.

Bile acids and gut microbiota play a central role in the development of IFALD and make attractive biomarkers as well as therapeutic targets. A multitarget, individualised therapy aiming at different parts of the BA-GM axis may provide optimal clinical benefits and requires future investigation.